In this study we relied on screens that were set-up to resemble clinical treatment scenarios for EGFR mutant lung cancer, using NSCLC cancer cell lines harboring EGFR mutations commonly found in patient populations and where those cell lines were treated with 1st or 3rd generation EGFR inhibitors. Here, EGFR is linked to lung carcinoma.